A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
Premier responded to a request for information (RFI) from the Federal Trade Commission (FTC) on how business practices of pharmacy benefit managers (PBMs) affect patients, doctors, employers, pharmacies and other businesses in the prescription drug space. In its response, Premier describes how a host of PBM practices result in negative consequences for patients and stifle competition. These harmful practices include rebates and formulary placements, PBM preferred products, “white bagging,” pharmacy price concessions (direct and indirect remuneration (DIR)) and discriminatory 340B pricing. Premier urges the FTC to investigate the practices of PBMs and recommends that PBM transparency standards: